Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Junshi Biosciences
Pharma
AbbVie-FutureGen, Takeda, Kyowa Kirin—Fierce Pharma Asia
AbbVie ventures into TL1A via a Chinese biotech. An ex-Takeda staffer pleaded guilty to scamming the firm. Kyowa Kirin will invest $530 million in NC.
Angus Liu
Jun 14, 2024 5:00am
Junshi, Coherus move Loqtorzi closer to another approval
Jun 12, 2024 11:45am
AstraZeneca, BeiGene, Coherus—Fierce Pharma Asia
Dec 1, 2023 8:34am
Coherus prices China-made PD-1 at 20% discount to Keytruda
Nov 27, 2023 6:10pm
Hengrui, Takeda, and toripalimab's FDA nod—Fierce Pharma Asia
Nov 3, 2023 8:30am
Coherus spurns 'heavily discounted' pricing for new PD-1 med
Oct 30, 2023 12:10pm
